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Abstract
Background: This cross-sectional study was conducted to compare the average costs of breast cancer screening 
and treatment among women with the age of 25 and over in Shiraz-Iran. 
Methods: Three majors hospitals affiliated with Shiraz University of Medical Sciences (SUMS) were 
selected for data collection. Financial documents and interviews with the hospitals’ financial officers were 
used for data collection. 
Results: Finding shows that the total cost of screening would be 5,847,544.96 US dollars for age groups of 25–34 
and 35 and above, demonstrating the huge expense of screening programs. On the other hand, the average cost 
of breast cancer treatment for each patient would be 3608.47, 996.89, and 311.47 US dollars for mastectomy, 
radiotherapy, and chemotherapy, respectively. In addition, the total average cost for treatment of 2217 patients 
would be 1,466,988.9 US dollars, which is much less than screening programs expenses. 
Conclusion: It is concluded that although screening can be effective for improving quality of life and treatment 
effectiveness, considering the high costs of screening, it is not economical in Iran. Screening methods within 
suitable intervals, and also considering patients’ medical history have been recommended by the present study.
Keywords: Breast Cancer, Screening, Treatment, Cost-Effectiveness
Copyright: © 2014 by Kerman University of Medical Sciences
Citation: Hatam N, Keshtkar V, Salehi A, Rafei H. The financial cost of preventive and curative programs 






Received: 14 January 2014
Accepted: 4 May 2014
ePublished: 8 May 2014
Original Article
Full list of authors’ affiliations is available at the end of the article.
http://ijhpm.com
Int J Health Policy Manag 2014, 2(4), 187–191 doi 10.15171/ijhpm.2014.44
Introduction
Cancer is considered as a major issue concerning healthcare 
systems. Due to the global increases in cancer prevalence, 
and its attribution to more than 12% of the world’s mortality, 
providing efficient policies for cancer screening and treatment 
is recognized as the leading priority of healthcare systems (1,2).
According to the literature, five common factors that contribute 
to increasing cancer rates in both developed and developing 
countries include dietary changes, smoking, infections, 
occupational and agronomic problems, and environmental 
pollution. Among these, dietary factors and infections alone 
contributed to 4.4 out of 10 million cancers in 2002 (3,4).
In Iran, cancer is the third leading cause of mortality, 
following accidents and heart disease. 30,000 individual 
deaths are attributed to cancer annually. Additionally, Iran 
experiences more than 70,000 new cancer cases annually, and 
this figure could potentially double in the next two decades 
due an aging population (4). 
Breast cancer is the most common cancer in women, and the 
second highest contributor to cancer mortality. It accounts 
for 20% of deaths in women aged 40 to 50 years (5), and 
32% of women’s cancers, and 19% of women’s cancer deaths, 
are attributed to breast cancer (6). Considering the current 
inconclusive knowledge regarding the nature of cancers, 
cancer-management solutions should focus on prevention, 
early detection, control, and cure (7).
According to World Health Organization (WHO) statistics, 
breast cancer prevalence rates presently increase by 1.8 to 2 
yearly. Notably, 25% of all detected cases are in developed 
stages (5). Detection and preventive methods for breast cancer 
(breast sonography and mammography) are the most effective 
methods in the initial stages of breast cancer, otherwise 
increasingly complex treatments such as mastectomy, 
radiotherapy, and chemotherapy are utilised. However, such 
methods impose high costs for patients and hospitals (8).
In developed countries, cancer screening is part of a national 
plan, which includes training for early detection, while in 
developing countries such as Iran, cancer screening is not 
yet institutionalized (8). A majority of cases in developed 
countries are detected and cured in stage 1, while in Iran many 
of cases are detected in the second or third stages, creating 
challenges for treatment (8).
According to the above information, breast cancer bears a high 
prevalence rate, and is an important social and health issue (9). 
However the presently increasing population creates a strain 
on available resources, particularly in developing countries, 
which necessitate optimized utilization of financial resources 
(9). Thus, it is necessary for healthcare service managers and 
specialists to computation technology for effective health 
services in order to optimize resource assignment (10). 
Considering breast cancer prevalence in the Fars province and 
the necessity of mammography and sonography, this study has 
been conducted to show the financial cost of mammography 
and sonography screening program for preventive and 
curative procedures among women with the age of 25 and 
over in Shiraz-Iran.
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Methods
This cross-sectional study has been conducted in 2007 
(one year) in hospitals affiliated with Shiraz University 
of Medical Sciences (SUMS), including Shahid Faghihi, 
Hafez and Namazi hospitals. The study population includes 
two groups: 1) patients referred to Hafez hospital for 
sonography and mammography for breast cancer detection, 
and 2) patients referred to Shahid Faghihi hospital for 
mastectomy services, or to Namazi hospital for chemotherapy 
and radiotherapy services. 
Among the patients referred to Hafez hospital, 225 
were referred for sonography and 494 were referred for 
mammography services. 196 cases were referred to Shahid 
Faghihi hospital for mastectomy; 190 and 1831 to Namazi 
hospital for radiotherapy and chemotherapy, respectively. It 
should be noted that all cases were selected in the sample, due 
to the limited numbers of patients.
Data observation, financial documents and interviews with 
the hospitals’ financial officers were used in data collection. 
Cost information was also based on the national tariff. 
For estimating the at-risk population requiring sonography 
and mammography, data related to women aged 25–34 
years and above 35 years, respectively, was extracted from 
the statistical report of the Fars governmental programming 
deputy. Costs were then computed and compared in order to 
clarify the resource assignment process. Two costs, namely 
those related to cancer prevention actions and costs related to 
treatment were compared in this study. 
Results
Findings show that the average costs of breast sonography and 
mammography per patient were 3.13 and 10.98 US dollars 
respectively for the hospital (the average cost was estimated 
based on the prime cost; Table 1). The average expense of 
breast sonography and mammography incurred by each 
patient was 4.45 and 11.70 US dollars respectively. This shows 
that hospitals do not incur any additional costs for these 
services, as the cost is covered by patients.
Considering that mammography is the most suitable 
method for screening among women aged 35 years and over, 
sonography is generally used for patients under 35 years. 
Therefore, computations were completed in two different age 
groups to calculate the costs of screening, as follows:
• In accordance with annual statistics (2005), there were 
265,627 women aged 25 to 34 years in Fars province. 
Assuming that they use sonography, at a cost of 3.14 US 
dollars per person, the total sonography cost would be 
834,068.78 US dollars.
• In accordance with annual statistics (2007), there were 
456,508 women above 35 years of age in Fars province. 
Considering that the cost of mammography is 10.98 
US dollars, the total cost for mammography would be 
5,012,457.84 US dollars.
Therefore, the total cost of screening would be 5,845,490.67 
US dollars for age groups of above 35 and 25–34 (Table 2), 
demonstrating the huge expense of screening programs. On 
the other hand, the average cost of breast cancer treatment 
for each patient is 3608.47, 996.89, and 311.47 US dollars for 
mastectomy, radiotherapy, and chemotherapy, respectively. 
The total average cost to treat 2217 patients would be 
1,466,988.90 US dollars (Table 3), which is much less than 
screening programs expenses.
Discussion and Conclusion
Cancer is considered as a global health imperative. It is 
predicted that cancer will become the leading cause of 
death by 2030 due to an aging population, relative control of 
infectious diseases, and increasing cancer risk factors such as 
pollution. Therefore providing efficient cancer-management 
techniques is essential in health systems (11).
Table 1. Costs of sonography and mammography for each patient in Hafez hospital in 2007
Hafez hospital costs
Costs of sonography Cost of mammography 
IRR $ IRR $
Water cost 33 0.00 464 0.04
Energy cost 14 0.00 197 0.01
Natural gas coast 18 0.00 255 0.02
Telephone cost 8 0.00 116 0.01
Maintenance cost 88 0.00 1232 0.12
Building depreciation cost 330 0.03 4596 0.45
Security cost 208 0.02 2909 0.29
Transportation cost 80 0.00 1123 0.11
Cleaning services cost 485 0.04 6777 0.67
Data processing cost 121 0.01 1751 0.17
Waste disposal cost 9 0.00 123 0.01
Consumption material costs 5602 0.56 18365 1.83
Personnel cost 19959 1.99 45617 4.56
Staff uniform clothes cost 196 0.01 2210 0.22
Cost of equipment depreciation 4210 0.42 24110 2.41
Total cost 31361 3.13 109845 10.98
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Breast cancer is one of the most prevalent cancers worldwide. 
Although breast cancer is common in both developed and 
developing countries, its prevalence is increasing in the 
developing world due to increased life expectancy, increased 
urbanization, and adoption of western lifestyles (5). In 
addition, these countries experience high case fatality rates, 
likely due to a lack of awareness of the benefits of detection 
and treatment, a scarcity of adequate facilities for detection 
and diagnosis, as well as poor access to primary treatment (5). 
Therefore, the necessity of using screening methods such as 
sonography and mammography for detecting and preventing 
this cancer is evident (12).
The importance of detecting breast cancer during the first 
stages has been highlighted by many studies. For example 
Anderson et al. emphasized on the role of mammography 
in reducing cancer returns (13). Zwahlen et al. revealed that 
breast cancer patients would have a greater chance of survival 
if the disease is detected in its initial stages (14). Therefore, 
early detection is an important step towards reducing the 
physical and mental impacts of breast cancer. Evidence 
shows that general systematic invitations to breast imaging, 
for women aged 50–69 years, can reduce breast cancer risk 
up to 25% (14,15).
In addition to planned screening, the quality and duration 
of screening are also important prevention/detection factors. 
Anderson et al. stated that systematic breast imaging every 
two years can help to detect the disease in its initial stages 
(13). Some evidence suggests that regular screening can 
reduce the risk of breast cancer by 30% in women aged over 
50 years, as early detection allows more effective treatment, 
at lower costs (13). Lebovic et al. emphasized the importance 
of screening in the USA (16). Pisati et al. also examined 
417 under X-ray employees during 2002–9 with cancer 
screening methods, in which the participation rate, the 
premalignant and malignant findings, and cost-effectiveness 
are consistent with the suggestion that cancer screening 
programs can be implemented as health promotion activities 
in healthcare workers (17).
According to the statistics, the prevalence rate of breast cancer 
in Iran’s Fars province is 6.7 per 1000 for women aged over 35 
years (456,508 individuals) (18), which shows an estimation 
of 3058 individuals. Assuming an average treatment cost 
of 661.70 US dollars per patient, the total cost for treating 
afflicted individuals will be 2,023,478.60 US dollars. Compared 
with annual mammography screening costs, calculated to 
be 2,991,031.38 US dollars in the previous section, these 
figures suggest cost-ineffectiveness of screening in women 
aged over 35 years. Grann et al. also suggested that surgery is 
more cost-effective than screening, as annual mammography 
imposes high costs (19), which is consistent with our findings. 
However some of the studies such as Smith and Zwahlen et al. 
emphasized on the effectiveness of screening methods, while 
there is a good insurance coverage for that (14,20). 
Breast cancer prevalence for women aged 25–34 years was 
9.16 per 100,000 in Fars province. According to Mehrabani 
et al. study in 2008 (21), the expected breast cancer cases in 
this age group (n= 265,627) is 24.33. Therefore, considering 
the costs of screening using sonography (833,032.83 US 
dollars), and the expected cases’ treatment costs (16,099.17 
US dollars), sonographic screening is shown to be ineffective 
in comparison with treatment (816,933.65 US dollars). 
This reveals that sonography, like mammography, requires 
more funding than treatment. Therefore, it appears that 
screening is not economical for this sample population, and 
it is recommended to perform screening in accordance with 
patients’ health history and age. Thus, in this study, screening 
was performed with different time interventions such as 2 or 
3 years and the obtained results suggested that: 
• Assuming screening with mammography takes place 
every 2 years in Fars province, the total costs of breast 
cancer screening for the above 35 years age group 
will be 5,014,512.12 US dollars. Comparing this value 
with treatment costs of 4,046,961.48 US dollars shows 
the cost-ineffectiveness of screening methods about 
967,550.64 US dollars.
• Assuming screening with sonography takes place 
every 2 years in Fars province, the total costs of breast 
cancer screening for women aged between 25–34 years 
group will be 833,032.38 US dollars. Comparing this 
value with treatment costs of 32,198.35 US dollars 
shows the cost-ineffectiveness of screening methods 
800,834.47 US dollars.
• Assuming screening with mammography every 3 years 
in Fars province, the total cost of breast cancer screening 
for the above 35 years age group will be 6,070,442.22 US 
Table 2. Costs of breast cancer screening method in Fars province in 2007
Diagnostic services
The study population (on the basis of 
Fars province statistical calendar in 2005)
The prime cost per each patient The total cost for breast cancer screening
IRR $ IRR $
Breast sonography 265627 (age: 25-34) 31361 3.14 8,340,687,847 834,068.78
Mammography 456508 (age: 35+) 109845 10.98 50,124,578,460 5,012,457.84
Table 3. Costs of treatment methods in under study population in 2007
Treatment services Number
The average of payment per patient The patient payment per year
IRR $ IRR $
Radiotherapy 190 9968925 996.89 1,894,095,780 189,409.57
Mastectomy 196 36084790 3608.47 7,072,618,992 707,261. 89 
Chemotherapy 1831 3114796 311.47 5,703,191,490 570,319.14
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dollars, which shows higher efficiency of 1,055,930 US 
dollars in compare with treatment.
• For sonography in women aged 25–34 years in Fars 
province, the findings also showed that the sonography 
cost with interval of three years is 833,032.38 US dollars 
which is not cost-effective with the amount of 784,728.23 
US dollars in comparison with treatment cost (48,304.15 
US dollars). Therefore it appears that screening is 
not effective for 25–34 year old group, even if when 
performed every three years.
Consistent with these findings, other studies also revealed that 
yearly screening is not cost-effective. For example, Schousboe 
et al. studied breast cancer screening using mammography for 
40–50 year old women in California, and concluded that the 
cost of this plan is lower than 100,000 US dollars per Quality 
Adjusted Life Year (QALY) for women aged 40–79 years. 
The cost of 40–49 year old women was 50000 US dollars per 
QALY. This shows that annual mammography is not cost-
effective for all age groups. Thus, the general consensus is 
that mammography should be performed based on age, breast 
density, breast biopsy history, and family history (22). Boer 
et al. also studied the effectiveness of decreasing the imaging 
interval from 3 years to 2 years, however with increasing the 
average age from 64 years to 69 in Britain. They concluded 
that both of these changes increase survival and enhance 
the health efficiency (23). On the other hand, Stout et al. 
study revealed that the death rate due to breast cancer has 
gradually decreased in the USA in recent decades, partly due 
to disciplined screening. This study suggested that in 2001, 
about 70% of American women had performed at least one 
screening in last two years. This study showed the cost-
effectiveness of breast cancer imaging in 1–2 year intervals for 
women aged over 40 years (24), which is not consistent with 
our results, and may be due to different healthcare systems in 
the US and Iran. 
Peregrino et al. also considered screening methods such as 
mammography and other methods per 2-year intervals as a 
default. He has studied four scenarios, namely disease history, 
mammography, digital mammography, and imaging and used 
Markov’s biannual model for 100,000 individuals. Although 
results suggested that these methods have different costs, and 
the difference of effectiveness was between 300 to 78,000 total 
years of survival, it was concluded that mammography is the 
most cost-effective scenario (25).
Although many of studies reveal that the screening methods 
are very useful for detecting and preventing diseases, 
especially breast cancer, they emphasize that some factors 
such as screening interval, target population, age, and 
detection method are important for cost-effectiveness of 
cancer treatment methods. For example Verbeek et al. studied 
5 kinds of cancer such as breast, cervical, colorectal, prostate, 
and lung, and uncovered some serious problems associated 
with screening, such as unnecessary referrals for certain 
detection in hospital (26).
It is concluded that screening especially for women aged over 40 
years can be considered an effective tool for improving quality 
of life and treatment effectiveness. However, considering the 
high costs of screening, it is not economical in most countries. 
Limitations
One of the limitations of the present study is that the cost of 
screening programs is not certain and precise as sensitivity, 
specificity and negative and positive predictive value of 
screening programs (mammography and sonography) which 
could affect the overall cost was not calculated in this study. 
The second limitation is that the costs of breast cancer occur 
over time (during several years). Therefore looking at only 
one year might not indicate true cost of treatment. 
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